Top-News

AMORFIX LIFE SCIENCE LTD. News

Keine aktuellen Kursdaten verfügbar
ISIN: CA0317221012
Typ: Aktie

AMORFIX LIFE SCIENCE LTD. News

14.11.19 - PR Newswire
ProMIS Neurosciences Announces Third Quarter 2019 Results
ProMIS Neurosciences Announces Third Quarter 2019 Results PR Newswire
07.11.19 - PR Newswire
ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
ProMIS Neurosciences outlines best-​in-class approach to amyloid-​beta-targeting drug candidates for Alzheimer's disease PR Newswire
24.10.19 - PR Newswire
ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease PR Newswire
23.10.19 - PR Newswire
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43 PR Newswire
17.10.19 - PR Newswire
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau PR Newswire
08.10.19 - PR Newswire
ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy PR Newswire
16.09.19 - PR Newswire
ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit
ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit PR Newswire
03.09.19 - PR Newswire
ProMIS Neurosciences to Present at HC Wainwright Investment Conference
ProMIS Neurosciences to Present at HC Wainwright Investment Conference PR Newswire
13.08.19 - PR Newswire
ProMIS Neurosciences Announces Second Quarter 2019 Results
ProMIS Neurosciences Announces Second Quarter 2019 Results PR Newswire
18.07.19 - PR Newswire
ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019 PR Newswire
10.07.19 - PR Newswire
ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference
ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference PR Newswire
09.07.19 - PR Newswire
ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports PR Newswire
27.06.19 - PR Newswire
ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-​Beta-Directed Antibodies PR Newswire
19.06.19 - PR Newswire
ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board PR Newswire
29.05.19 - PR Newswire
ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases
ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases PR Newswire
28.05.19 - PR Newswire
ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau
ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau PR Newswire
14.05.19 - PR Newswire
ProMIS Neurosciences Announces First Quarter 2019 Results
ProMIS Neurosciences Announces First Quarter 2019 Results PR Newswire
23.04.19 - PR Newswire
ProMIS Neurosciences to Participate in the Think Equity Investor Conference
ProMIS Neurosciences to Participate in the Think Equity Investor Conference PR Newswire
26.03.19 - PR Newswire
ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019 PR Newswire
21.03.19 - PR Newswire
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease PR Newswire

Newssuche

Videos

newspaper
16.04.24 0,00%
Technical Trading: Natural Gas Long Chance
Erdgas Long Typ: Turbo Open End WKN: VM6KAH Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »